B. Riley restated their buy rating on shares of Oramed Pharmaceuticals (NASDAQ:ORMP) in a research report report published on Tuesday morning. B. Riley currently has a $20.00 target price on the biotechnology company’s stock.
A number of other analysts also recently issued reports on the stock. HC Wainwright reiterated a buy rating and issued a $25.00 price objective on shares of Oramed Pharmaceuticals in a report on Wednesday, November 22nd. ValuEngine downgraded shares of Oramed Pharmaceuticals from a hold rating to a sell rating in a report on Tuesday, December 5th.
Shares of Oramed Pharmaceuticals (NASDAQ:ORMP) traded up $0.08 during mid-day trading on Tuesday, reaching $8.42. 20,258 shares of the company’s stock traded hands, compared to its average volume of 28,118. The firm has a market cap of $125.03, a P/E ratio of -10.94 and a beta of 0.34. Oramed Pharmaceuticals has a 52-week low of $5.85 and a 52-week high of $11.34.
Oramed Pharmaceuticals (NASDAQ:ORMP) last announced its earnings results on Wednesday, November 29th. The biotechnology company reported ($0.20) EPS for the quarter. Oramed Pharmaceuticals had a negative return on equity of 49.94% and a negative net margin of 169.17%. analysts forecast that Oramed Pharmaceuticals will post -1.31 earnings per share for the current year.
Hedge funds and other institutional investors have recently bought and sold shares of the company. Wells Fargo & Company MN raised its holdings in shares of Oramed Pharmaceuticals by 4.4% in the second quarter. Wells Fargo & Company MN now owns 14,725 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 625 shares during the last quarter. Virtu KCG Holdings LLC acquired a new stake in shares of Oramed Pharmaceuticals in the second quarter valued at approximately $125,000. Finally, Susquehanna International Group LLP acquired a new stake in shares of Oramed Pharmaceuticals in the third quarter valued at approximately $185,000. Institutional investors own 1.92% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece of content on another website, it was copied illegally and reposted in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/17/oramed-pharmaceuticals-ormp-receives-buy-rating-from-b-riley.html.
About Oramed Pharmaceuticals
Oramed Pharmaceuticals Inc (Oramed) is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. The Company is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.
Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.